DE69127175D1 - Antisens-Oligonukleotide zur Behandlung von Krebs - Google Patents
Antisens-Oligonukleotide zur Behandlung von KrebsInfo
- Publication number
- DE69127175D1 DE69127175D1 DE69127175T DE69127175T DE69127175D1 DE 69127175 D1 DE69127175 D1 DE 69127175D1 DE 69127175 T DE69127175 T DE 69127175T DE 69127175 T DE69127175 T DE 69127175T DE 69127175 D1 DE69127175 D1 DE 69127175D1
- Authority
- DE
- Germany
- Prior art keywords
- antisense oligonucleotides
- cancer
- treatment
- animals
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60711390A | 1990-11-02 | 1990-11-02 | |
US68019891A | 1991-04-05 | 1991-04-05 | |
US07/702,163 US5271941A (en) | 1990-11-02 | 1991-05-20 | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69127175D1 true DE69127175D1 (de) | 1997-09-11 |
DE69127175T2 DE69127175T2 (de) | 1998-03-12 |
Family
ID=27416969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69127175T Expired - Fee Related DE69127175T2 (de) | 1990-11-02 | 1991-10-31 | Antisens-Oligonukleotide zur Behandlung von Krebs |
DE69132299T Expired - Fee Related DE69132299T2 (de) | 1990-11-02 | 1991-10-31 | Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von Krebs |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69132299T Expired - Fee Related DE69132299T2 (de) | 1990-11-02 | 1991-10-31 | Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von Krebs |
Country Status (9)
Country | Link |
---|---|
US (3) | US5271941A (de) |
EP (3) | EP0972831A1 (de) |
KR (1) | KR0171210B1 (de) |
AT (2) | ATE156517T1 (de) |
CA (2) | CA2488792A1 (de) |
DE (2) | DE69127175T2 (de) |
DK (2) | DK0490077T3 (de) |
ES (2) | ES2148838T3 (de) |
GR (2) | GR3024673T3 (de) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US5646267A (en) * | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US5359052A (en) * | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US6995146B2 (en) * | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
JPH08508405A (ja) | 1993-03-26 | 1996-09-10 | トーマス ジェファーソン ユニバーシティ | Igf−1レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法 |
US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
ES2326118T3 (es) * | 1993-09-20 | 2009-10-01 | The Trustees Of The University Of Pennsylvania | Regulacion de la expresion del gen bcl-2. |
US5618709A (en) * | 1994-01-14 | 1997-04-08 | University Of Pennsylvania | Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein |
US5726297A (en) * | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
US5599922A (en) * | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US6608035B1 (en) * | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
US7074768B2 (en) * | 1995-08-17 | 2006-07-11 | Idera Pharmaceuticals, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US20050054600A1 (en) * | 1995-08-17 | 2005-03-10 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotides and methods of their use |
US5969117A (en) * | 1995-08-17 | 1999-10-19 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotide |
US6624293B1 (en) * | 1995-08-17 | 2003-09-23 | Hybridon, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
ATE339498T1 (de) * | 1997-03-12 | 2006-10-15 | Idera Pharmaceuticals Inc | Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US6312941B1 (en) | 1997-11-26 | 2001-11-06 | The Regents Of The University Of Michigan | Compositions and methods for identifying signaling pathway agonists and antagonists |
AU5618700A (en) * | 1999-06-18 | 2001-01-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer |
US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US6489356B2 (en) | 2000-09-05 | 2002-12-03 | Edward Leung | Method for treating pain in humans |
EP1330544A4 (de) | 2000-09-26 | 2005-04-06 | Univ Duke | Rna-aptamere und verfahren zu deren identifizierung |
EP2336166A1 (de) | 2000-10-12 | 2011-06-22 | University Of Rochester | Zusammensetzungen die die Proliferation von Krebszellen hemmen |
KR100408916B1 (ko) * | 2000-11-23 | 2003-12-11 | 주식회사 바이오제니아 | 마이코락톤을 함유하는 항암제, 사람 레티노블라스토마단백질의 발현을 저하시키는 안티센스 올리고누클레오티드및 마이코락톤과 상기 안티센스 올리고누클레오티드를함유하는 항암제 |
US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
EP1572168B1 (de) | 2002-02-06 | 2010-05-26 | Vicor Technologies, Inc. | Anti-infarkt-moleküle |
EP1534729A2 (de) * | 2002-02-26 | 2005-06-01 | University of Utah Research Foundation | Mit bluthochdruck und virusknospung assoziierte nedd4l-varianten |
EP1575992A4 (de) | 2002-08-05 | 2007-02-21 | Univ Rochester | Chimäre proteine aus proteintransduzierender domäne/deaminase, verwandte verbindungen und deren verwendungen |
WO2004053073A2 (en) * | 2002-12-05 | 2004-06-24 | The Research Foundation Of State University Of Newyork | HIGH EFFICACY ANTISENSE Riα PKA POLY-DNP OLIGORIBONUCLEOTIDES |
WO2006031210A1 (en) | 2003-05-29 | 2006-03-23 | Board Of Regents, The University Of Texas Systems | Jabi as a prognostic marker and a therapeutic target for human cancer |
US8029815B2 (en) * | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
EP1765065B1 (de) | 2004-05-21 | 2012-06-27 | University of Utah Research Foundation | Verfahren und zusammensetzungen für die abgabe von chemikalien an embryonen von wirbellosen |
EP2484780A1 (de) | 2004-07-23 | 2012-08-08 | The University of North Carolina At Chapel Hill | Verfahren und Materialien zur Bestimmung der Schmerzempfindlichkeit und Vorhersage und Behandlung zugehöriger Störungen |
ES2716874T3 (es) | 2005-03-23 | 2019-06-17 | Genmab As | Anticuerpos contra cd38 para el tratamiento del mieloma múltiple |
US8703769B2 (en) * | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
CA2625891A1 (en) | 2005-10-14 | 2007-04-26 | Carlton D. Donald | Inhibition of pax2 by defb1 induction as a therapy for cancer |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
WO2008017473A2 (en) | 2006-08-08 | 2008-02-14 | Gunther Hartmann | Structure and use of 5' phosphate oligonucleotides |
EP2560001B1 (de) | 2006-09-21 | 2016-04-13 | University of Rochester | Zusammensetzungen und Verfahren für eine Proteinverlagerungstherapie für myotone Dystrophie |
US8999317B2 (en) | 2006-11-01 | 2015-04-07 | University Of Rochester | Methods and compositions related to the structure and function of APOBEC3G |
JP2010512327A (ja) | 2006-12-11 | 2010-04-22 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 病的血管形成および脈管透過性の処置用の組成物および方法 |
EP2030615A3 (de) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen |
AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
AU2008296487A1 (en) | 2007-08-28 | 2009-03-12 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
US7828840B2 (en) * | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
WO2010070380A2 (en) * | 2007-12-03 | 2010-06-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health | Doc1 compositions and methods for treating cancer |
US20110262395A1 (en) | 2008-05-08 | 2011-10-27 | University Of Utah Research Foundation | Sensory receptors for chronic fatigue and pain and uses thereof |
JP5689413B2 (ja) | 2008-05-21 | 2015-03-25 | ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン | 平滑末端を有する5’三リン酸オリゴヌクレオチドおよびその使用 |
US8816095B2 (en) * | 2008-08-15 | 2014-08-26 | Georgetown University | Na channels, disease, and related assays and compositions |
US20120070443A1 (en) | 2008-12-02 | 2012-03-22 | University Of Utah Research Foundation | Pde1 as a target therapeutic in heart disease |
WO2011031974A1 (en) | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
EP2580243B1 (de) | 2010-06-09 | 2019-10-16 | Genmab A/S | Antikörper gegen menschliches cd38 |
EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
WO2014093688A1 (en) | 2012-12-12 | 2014-06-19 | 1Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
WO2015077566A1 (en) | 2013-11-21 | 2015-05-28 | Huang Zhen | Methods for structural determination of selenium derivatized nucleic acid complexes |
BR112017001860A2 (pt) | 2014-07-31 | 2018-02-27 | Uab Research Foundation | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal |
MX2017010066A (es) | 2015-02-04 | 2017-11-01 | Hoffmann La Roche | Oligomeros antisentido de tau y usos de los mismos. |
CN115181778A (zh) | 2015-02-04 | 2022-10-14 | 百时美施贵宝公司 | 选择治疗性分子的方法 |
JP2019527229A (ja) | 2016-07-28 | 2019-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Gpr156変異体及びその使用 |
US11123435B2 (en) | 2016-08-03 | 2021-09-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TLR9 targeted therapeutics |
KR102619197B1 (ko) | 2017-01-23 | 2024-01-03 | 리제너론 파마슈티칼스 인코포레이티드 | Hsd17b13 변종 및 이것의 용도 |
CA3065938A1 (en) | 2017-06-05 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | B4galt1 variants and uses thereof |
AU2018328120A1 (en) | 2017-09-06 | 2020-03-19 | Regeneron Pharmaceuticals, Inc. | Single immunoglobulin interleukin-1 receptor related (SIGIRR) variants and uses thereof |
RU2020112313A (ru) | 2017-09-07 | 2021-10-08 | Ридженерон Фармасьютикалз, Инк. | Варианты члена 1 семейства 14 переносчиков растворенных веществ (slc14a1)и их применение |
US12016314B2 (en) | 2017-09-08 | 2024-06-25 | Ohio State Innovation Foundation | MicroRNA inhibitor therapy in systemic lupus erythematosus |
EP3695012B1 (de) | 2017-10-11 | 2023-03-08 | Regeneron Pharmaceuticals, Inc. | Hemmung von hsd17b13 in der behandlung der lebererkrankung bei patienten, die die pnpla3-i148m-variation exprimieren |
EP3697807A1 (de) | 2017-10-16 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Cornulin (crnn)-varianten und ihre verwendungen |
US11957687B2 (en) | 2019-07-02 | 2024-04-16 | Regeneron Pharmaceuticals, Inc. | Modulators of HSD17B13 and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
NO864301L (no) * | 1986-10-28 | 1988-04-29 | Tore Jahnsen | Dna-prober for human regulatorisk enhet av camp-avhengige proteinkinaser. |
EP0424473B1 (de) * | 1988-07-05 | 1996-05-08 | Baylor College Of Medicine | Verfahren zur identifizierung von bakterien |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
-
1991
- 1991-05-20 US US07/702,163 patent/US5271941A/en not_active Expired - Lifetime
- 1991-10-28 CA CA002488792A patent/CA2488792A1/en not_active Abandoned
- 1991-10-28 CA CA002054325A patent/CA2054325C/en not_active Expired - Fee Related
- 1991-10-31 EP EP99119780A patent/EP0972831A1/de not_active Withdrawn
- 1991-10-31 AT AT91118628T patent/ATE156517T1/de not_active IP Right Cessation
- 1991-10-31 ES ES97100277T patent/ES2148838T3/es not_active Expired - Lifetime
- 1991-10-31 EP EP97100277A patent/EP0785252B1/de not_active Expired - Lifetime
- 1991-10-31 ES ES91118628T patent/ES2104644T3/es not_active Expired - Lifetime
- 1991-10-31 EP EP91118628A patent/EP0490077B1/de not_active Expired - Lifetime
- 1991-10-31 DE DE69127175T patent/DE69127175T2/de not_active Expired - Fee Related
- 1991-10-31 DE DE69132299T patent/DE69132299T2/de not_active Expired - Fee Related
- 1991-10-31 DK DK91118628.6T patent/DK0490077T3/da active
- 1991-10-31 AT AT97100277T patent/ATE194383T1/de not_active IP Right Cessation
- 1991-10-31 DK DK97100277T patent/DK0785252T3/da active
- 1991-11-02 KR KR1019910019468A patent/KR0171210B1/ko not_active IP Right Cessation
-
1993
- 1993-05-14 US US08/060,984 patent/US5627158A/en not_active Expired - Fee Related
-
1995
- 1995-02-02 US US08/383,742 patent/US5691317A/en not_active Expired - Fee Related
-
1997
- 1997-09-10 GR GR970402319T patent/GR3024673T3/el unknown
-
2000
- 2000-10-02 GR GR20000402225T patent/GR3034535T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0972831A1 (de) | 2000-01-19 |
EP0785252B1 (de) | 2000-07-05 |
CA2054325C (en) | 2005-03-15 |
ATE156517T1 (de) | 1997-08-15 |
ES2104644T3 (es) | 1997-10-16 |
EP0785252A1 (de) | 1997-07-23 |
EP0490077A1 (de) | 1992-06-17 |
ATE194383T1 (de) | 2000-07-15 |
GR3024673T3 (en) | 1997-12-31 |
DE69132299D1 (de) | 2000-08-10 |
US5627158A (en) | 1997-05-06 |
DK0785252T3 (da) | 2000-10-02 |
KR0171210B1 (ko) | 1999-02-01 |
CA2488792A1 (en) | 1992-05-03 |
DE69127175T2 (de) | 1998-03-12 |
CA2054325A1 (en) | 1992-05-03 |
GR3034535T3 (en) | 2001-01-31 |
DK0490077T3 (da) | 1998-01-26 |
DE69132299T2 (de) | 2001-02-15 |
US5271941A (en) | 1993-12-21 |
US5691317A (en) | 1997-11-25 |
ES2148838T3 (es) | 2000-10-16 |
EP0490077B1 (de) | 1997-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69127175D1 (de) | Antisens-Oligonukleotide zur Behandlung von Krebs | |
DE69310634D1 (de) | Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs | |
DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
BR9814857A (pt) | Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril | |
ATE184792T1 (de) | 2-bromomelatonin zur behandlung von schlafstörungen | |
BR9502707A (pt) | Composto composição farmacêutica e método para o tratamento de uma afecção | |
DE3856594D1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
DE3870508D1 (de) | Zusammensetzung zur behandlung des haares. | |
DE3882775D1 (de) | Zusammensetzung zur behandlung von parodontaler krankheit. | |
BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
HUT51594A (en) | Process for production of celates and their complexes containing ortolizating functional groups, compositions containing such active substances and process for production of conjugates consisting of one complex and linked to it antibody or fragment of antibody | |
DE69429806D1 (de) | Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung | |
DE69233725D1 (de) | Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren | |
ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
DE3686811D1 (de) | Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren. | |
ATE159171T1 (de) | Arzneimittelzusammensetzung enthaltend tcf-ii | |
ATE22282T1 (de) | Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen. | |
DE69111457D1 (de) | Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien. | |
DE68913995D1 (de) | Zusammensetzung zur behandlung progressiver myopie. | |
DE69000960D1 (de) | Zusammensetzung zur behandlung von pigmentierung. | |
DE69425345D1 (de) | Anwendung von Selegilin in Tiermedizin | |
DE69112718D1 (de) | Verfahren und Zusammensetzung zur Behandlung von tierischen Exkrementen. | |
DE3782661D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von krebs. | |
DE69732851D1 (de) | Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |